Zhejiang Tasln Biopharma Co., Ltd.: FDA NDC listings

Does Zhejiang Tasln Biopharma Co., Ltd. list GLP-1 drug products with FDA?

Yes. FDA’s NDC Directory files, read Nov 15, 2026, list 4 products naming semaglutide and tirzepatide under the labeler name “Zhejiang Tasln Biopharma Co., Ltd.”, in these marketing categories: BULK INGREDIENT (2); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (2). A listing is the labeler’s own submission; FDA says it does not indicate that FDA has verified the information or that the product is FDA-approved.

GLP-1 listings
4
Marketing categories
BULK INGREDIENT (2); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (2)
Drugs named
Semaglutide, Tirzepatide
Marketing start dates
Nov 5, 2025 to Mar 11, 2026

This page exists because the labeler has 2 or more compounded or bulk ingredient GLP-1 listings in FDA’s NDC files and no other page here under the same name. FDA’s NDC files give a labeler name, not an address or FEI number, so this index has not tied this labeler to any FDA inspection, letter or import record.

Listings

84643-101Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTNov 5, 2025None givenDec 31, 2026Unfinished drugs
84643-101Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGFeb 12, 2026None givenDec 31, 2027Unfinished drugs
84643-102Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTFeb 5, 2026None givenDec 31, 2026Unfinished drugs
84643-102Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGMar 11, 2026None givenDec 31, 2027Unfinished drugs

FDA’s own words on the NDC Directory page (content current as of Mar 4, 2026):

Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved. The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file. Assignment of an NDC number does not in any way denote FDA approval of the product. Any representation that creates an impression of FDA approval because a product has an NDC number is misleading and violates federal law. Inclusion in the NDC Directory or assignment of an NDC number does not mean a product is a drug as defined by federal law.

All GLP-1 NDC listings.

This page restates listings from FDA’s NDC Directory files as FDA publishes them. A listing is the labeler’s own submission to FDA, not an FDA approval and not a finding by this site, and it says nothing about inspections or enforcement. Follow the source link for FDA’s files. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.